Table 2.
Primary end points at baseline and week 48 for patients with C3G (ITT and PP populations)
| Parameter, mean (SD) | ITT | PP |
|---|---|---|
| Baselinea | ||
| Number of patients | 8 | 4 |
| 24-hour UPCR, mg/mg | 3.3 (1.7) | 3.5 (2.1) |
| Week 48 | ||
| Number of patients | 7 | 4 |
| 24-hour UPCR, mg/mg | 1.2 (0.8) | 1.0 (0.7) |
| Individual CFB (SD) in 24-hour UPCR, mg/mgb | −2.0 (2.0) | −2.5 (2.5) |
| Individual %CFB (SD) in 24-hour UPCRb,c | −50.9 (39.1) | −65.4 (26.4) |
C3G, complement 3 glomerulopathy; CFB, change from baseline; ITT, intent-to-treat; PP, per-protocol; UPCR, urine protein-to-creatinine ratio.
a
Baseline was the most recent result prior to the first dose.
b
The means were calculated at each visit with only non-missing values.
c
The %CFB was determined for each individual patient as individual CFB divided by baseline UPCR, and then the mean of these individual %CFB was calculated.